Development and Functional Characterization of a Versatile Radio-/Immunotheranostic Tool for Prostate Cancer Management.
(18)F-JK-PSMA-7
Ac-225
CAR T cell
Cu-64
IgG4
PSCA
PSMA
prostate cancer
theranostics
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Apr 2022
14 Apr 2022
Historique:
received:
06
03
2022
revised:
08
04
2022
accepted:
11
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Due to its overexpression on the surface of prostate cancer (PCa) cells, the prostate stem cell antigen (PSCA) is a potential target for PCa diagnosis and therapy. Here we describe the development and functional characterization of a novel IgG4-based anti-PSCA antibody (Ab) derivative (anti-PSCA IgG4-TM) that is conjugated with the chelator DOTAGA. The anti-PSCA IgG4-TM represents a multimodal immunotheranostic compound that can be used (i) as a target module (TM) for UniCAR T cell-based immunotherapy, (ii) for diagnostic positron emission tomography (PET) imaging, and (iii) targeted alpha therapy. Cross-linkage of UniCAR T cells and PSCA-positive tumor cells via the anti-PSCA IgG4-TM results in efficient tumor cell lysis both in vitro and in vivo. After radiolabeling with
Identifiants
pubmed: 35454902
pii: cancers14081996
doi: 10.3390/cancers14081996
pmc: PMC9027777
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Helmholtz Initiative and Networking Fund (Radio-Immunotheranostics (MHELTHERA)
ID : InterLabs-0031
Organisme : Thematic Excellence Program of the Ministry for Innovation and Technology in Hungary
ID : 2020-4.1.1.-TKP2020
Organisme : European Union`s Horizon 2020 Teaming grant
ID : contract Nr. 739593 (HCEMM)
Références
Cancer Lett. 2006 May 18;236(2):229-38
pubmed: 16046056
MAbs. 2019 Nov-Dec;11(8):1341-1350
pubmed: 31556789
Cancers (Basel). 2012 Feb 22;4(1):193-217
pubmed: 24213236
Prostate Cancer Prostatic Dis. 2021 Sep;24(3):697-717
pubmed: 33820953
Clin Cancer Res. 2014 Dec 15;20(24):6367-78
pubmed: 25326233
J Autoimmun. 2013 May;42:105-16
pubmed: 23352111
Clin Cancer Res. 2022 May 2;28(9):1759-1764
pubmed: 35046063
Mol Ther. 2018 Nov 7;26(11):2542-2552
pubmed: 30415658
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
Lancet Oncol. 2019 Aug;20(8):e443-e451
pubmed: 31364596
J Med Chem. 2016 Mar 10;59(5):1761-75
pubmed: 26878194
Theranostics. 2018 Nov 12;8(21):5903-5914
pubmed: 30613270
Q J Nucl Med Mol Imaging. 2021 Dec;65(4):333-341
pubmed: 35133097
Clin Cancer Res. 2015 Dec 1;21(23):5277-85
pubmed: 26175541
Cancer Biother Radiopharm. 2000 Jun;15(3):235-44
pubmed: 10941530
Blood Cancer J. 2018 Aug 22;8(9):81
pubmed: 30190468
Methods. 2005 May;36(1):3-10
pubmed: 15848070
MAbs. 2014 Jul-Aug;6(4):928-42
pubmed: 24802048
Methods Mol Biol. 2022;2313:1-25
pubmed: 34478129
PLoS One. 2015 Jun 22;10(6):e0130249
pubmed: 26098691
DNA Cell Biol. 1998 Sep;17(9):751-9
pubmed: 9778034
Curr Oncol Rep. 2021 Mar 29;23(5):59
pubmed: 33778927
J Autoimmun. 2018 Jun;90:116-131
pubmed: 29503042
Clin Cancer Res. 2019 Mar 15;25(6):1702-1708
pubmed: 30413526
Mol Pharm. 2014 Nov 3;11(11):3980-7
pubmed: 24720806
Transl Androl Urol. 2021 Oct;10(10):3963-3971
pubmed: 34804839
Sci Rep. 2020 Feb 7;10(1):2141
pubmed: 32034289
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):139-147
pubmed: 30151743
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
Oncotarget. 2018 May 22;9(39):25597-25616
pubmed: 29876011
Nat Rev Dis Primers. 2021 Feb 4;7(1):9
pubmed: 33542230
Cancers (Basel). 2022 Jan 20;14(3):
pubmed: 35158771
Oncotarget. 2017 Sep 18;8(65):108584-108603
pubmed: 29312553
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2658-63
pubmed: 11226295
Bioconjug Chem. 2008 Mar;19(3):719-30
pubmed: 18254581
Oncotarget. 2017 Apr 29;8(33):54592-54603
pubmed: 28903367
Front Oncol. 2014 Jan 14;3:324
pubmed: 24459634
Nucl Med Biol. 2021 Jan;92:228-240
pubmed: 33558017
J Immunol. 2012 Feb 1;188(3):1551-8
pubmed: 22184723
Clin Exp Immunol. 1998 Apr;112(1):152-8
pubmed: 9566804
J Nucl Med. 2022 Jun;63(6):840-846
pubmed: 34503960
Prostate. 2018 Aug;78(11):775-789
pubmed: 29717499
J Med Chem. 2018 Oct 11;61(19):8774-8796
pubmed: 30180567
J Nucl Med. 2018 Sep;59(9):1398-1405
pubmed: 29602820
Oncoimmunology. 2017 Apr 28;6(6):e1323161
pubmed: 28680762
Oncoimmunology. 2020 Jul 3;9(1):1785608
pubmed: 32923149
J Immunother. 2007 May-Jun;30(4):396-405
pubmed: 17457214
Cancer Res. 2018 Feb 15;78(4):1031-1043
pubmed: 29222400
Nat Rev Urol. 2018 Jul;15(7):403-421
pubmed: 29769644
Prostate. 2014 Sep;74(13):1347-58
pubmed: 25053504
Clin Cancer Res. 2013 Sep 15;19(18):5182-91
pubmed: 23714732
J Clin Oncol. 2005 Jul 20;23(21):4591-601
pubmed: 15837970
Appl Radiat Isot. 2012 Apr;70(4):602-8
pubmed: 22326369
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):148-158
pubmed: 30090965
Sci Rep. 2021 Jul 29;11(1):15467
pubmed: 34326436
MMWR Morb Mortal Wkly Rep. 2020 Oct 16;69(41):1473-1480
pubmed: 33056955
Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1280-92
pubmed: 24577951
Oncoimmunology. 2020 Apr 5;9(1):1743036
pubmed: 32426176
Immunol Lett. 2019 Jul;211:13-22
pubmed: 31091431
J Exp Clin Cancer Res. 2020 May 5;39(1):77
pubmed: 32370811
J Nucl Med. 2019 Jun;60(6):817-823
pubmed: 30389823
Prostate. 2014 Sep;74(13):1335-46
pubmed: 25053443
J Immunol. 2012 Sep 15;189(6):3249-59
pubmed: 22875801
Cancer Med. 2021 Feb;10(3):1128-1140
pubmed: 33347715
Cancers (Basel). 2020 May 21;12(5):
pubmed: 32455621
Oncotarget. 2017 May 9;8(19):31368-31385
pubmed: 28404896
J Nucl Med. 2021 Feb;62(2):11N
pubmed: 33468545
Oncoimmunology. 2017 Feb 6;6(4):e1287246
pubmed: 28507794
EBioMedicine. 2020 Aug;58:102931
pubmed: 32739874
J Labelled Comp Radiopharm. 2014 Apr;57(4):224-30
pubmed: 24347474
Oncologist. 2020 Jun;25(6):477-e895
pubmed: 31999003
Lancet Oncol. 2019 Aug;20(8):e452-e463
pubmed: 31364597
Ther Drug Monit. 2017 Aug;39(4):327-332
pubmed: 28463887
Eur Urol Oncol. 2021 Oct;4(5):714-730
pubmed: 33750684
Blood Cancer J. 2016 Aug 12;6(8):e458
pubmed: 27518241
Inorg Chem. 2021 Jan 18;60(2):623-632
pubmed: 33213142
Int J Mol Sci. 2022 Jan 21;23(3):
pubmed: 35163083
Nucl Med Biol. 2000 May;27(4):375-80
pubmed: 10938473
Int J Mol Sci. 2021 Jan 26;22(3):
pubmed: 33530489
Clin Cancer Res. 2019 Feb 15;25(4):1142-1146
pubmed: 30309857
PLoS One. 2014 Apr 03;9(4):e93745
pubmed: 24699869
Blood. 2021 Jun 3;137(22):3145-3148
pubmed: 33624009
Chemistry. 2020 Feb 11;26(9):1989-2001
pubmed: 31755596
J Nucl Med. 2016 Dec;57(12):1941-1944
pubmed: 27390158
Cancer Res. 2007 Apr 15;67(8):3970-5
pubmed: 17440113
Cancer. 2019 Aug 1;125(15):2561-2569
pubmed: 31012963
Transl Lung Cancer Res. 2017 Apr;6(2):159-168
pubmed: 28529898
Nucl Med Biol. 2014 Jan;41(1):24-35
pubmed: 24183610
J Nucl Med. 2015 Aug;56(8):1169-76
pubmed: 26089548
Int J Mol Sci. 2018 Nov 21;19(11):
pubmed: 30469350
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1773-1784
pubmed: 33398412
Mol Immunol. 2011 Dec;49(3):474-82
pubmed: 22014687
Prostate. 2011 Jun 15;71(9):998-1011
pubmed: 21541976
Exp Cell Res. 1989 Nov;185(1):73-85
pubmed: 2530103
Methods Mol Biol. 2018;1853:27-30
pubmed: 30097926
Prostate. 2007 Jul 1;67(10):1121-31
pubmed: 17492652
Oncoimmunology. 2019 Sep 7;8(11):1659095
pubmed: 31646084
J Labelled Comp Radiopharm. 2019 Jun 30;62(8):533-540
pubmed: 30889625
J Am Chem Soc. 2019 Dec 11;141(49):19404-19414
pubmed: 31794205